TITLE

Angiotensin inhibition in the prevention of atrial fibrillation

AUTHOR(S)
Jenkins, Antoine T.
PUB. DATE
July 2009
SOURCE
Cardiology Today;Jul2009, Vol. 12 Issue 7, p5
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses the role of the inhibition of renin-angiotensin system (RAS) in preventing atrial fibrillation (AF).
ACCESSION #
42515395

 

Related Articles

  • Angiotensin Receptor Blockers for the Prevention of Atrial Fibrillation Recurrences: Unending Hot Debate. Celik, Turgay // JAFIB: Journal of Atrial Fibrillation; 

    The author reflects on the scientific basis for the notion that renin-angiotensin inhibition can reduce the incidence of atrial fibrillation (AF). He states that angiotensin receptor blockers (ARBs) shown to be effective in preventing AF despite the fact that it is limited to patients with...

  • The Role of Renin-Angiotensin System Blockade Therapy in the Prevention of Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials. Zhang, Y.; Zhang, P.; Mu, Y.; Gao, M.; Wang, J. R.; Wang, Y.; Su, L. Q.; Hou, Y. L. // Clinical Pharmacology & Therapeutics;Oct2010, Vol. 88 Issue 4, p521 

    Current evidence suggests that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) have emerged as novel drugs for preventing the development of atrial fibrillation (AF). A meta-analysis was performed of 26 randomized controlled clinical trials evaluating...

  • Age and CHADS2 Score Predict the Effectiveness of Renin-Angiotensin System Blockers on Primary Prevention of Atrial Fibrillation. Hung, Chen-Ying; Hsieh, Yu-Cheng; Li, Cheng-Hung; Huang, Jin-Long; Lin, Ching-Heng; Wu, Tsu-Juey // Scientific Reports;6/26/2015, p11442 

    Renin-angiotensin system (RAS) blockers have potential protective effects against atrial fibrillation (AF). The purpose of this study was to determine if patient characteristics and underlying co-morbidities could predict the efficacy of RAS blockers in AF prevention. Patients aged ≥ 45...

  • Non-Antiarrhythmic Drugs to Prevent Atrial Fibrillation. Moro, Concepción; Hernández-Madrid, Antonio; Matía, Roberto // American Journal of Cardiovascular Drugs;2010, Vol. 10 Issue 3, p165 

    Atrial fibrillation (AF) is the most frequent arrhythmia found in clinical practice. The majority of patients With AF are still candidates for antiarrhythmic drug treatment, not only for acute reversion to sinus rhythm but also for long-term treatment to prevent recurrences of AF. Currently...

  • AF and AD: reaching out to patients.  // Patient Care;12/15/1994, Vol. 28 Issue 20, p15 

    Focuses on the results of the Atrial Fibrillation Patient Notification Program in America. Sponsorship by the American College of Chest Physicians, National Stroke Association and Alliance for Aging Research; Availability of a toll-free counseling line; Availability of counseling services in...

  • Atrial fibrillation and stroke: What we know, what's new, and what we should do now. Landefeld, C. Seth // CMAJ: Canadian Medical Association Journal;09/15/97, Vol. 157 Issue 6, p695 

    Reports on ischemic stroke as the common cause of disability, dependency and death and occurs in many people with nonvalvular atrial fibrillation. What has been learned about the epidemiology and prevention of strokes; What we know; What is new; What we can do now.

  • Apoptosis coincident with the differentiation of skeletal myoblasts is delayed by caspase 3 inhibition and abrogated by MEK-independent constitutive Ras signaling. Dee, K.; Freer, M.; Mei, Y.; Weyman, C.M. // Cell Death & Differentiation;Feb2002, Vol. 9 Issue 2, p209 

    We demonstrate that during 23A2 skeletal myoblast differentiation, between 30-35% of the population apoptose. Both differentiation and apoptosis are controlled by the variables of cell density and time and these variables are inversely related. in response to conditions that permit both...

  • Interaction of Cyclosporine A and the Renin-Angiotensin System New Perspectives. Lassila, M. // Current Drug Metabolism;Feb2002, Vol. 3 Issue 1, p61 

    Despite extensive research, the exact mechanisms of cyclosporine A (CsA)-induced hypertension and nephrotoxicity remain obscure. Several lines of evidence suggest an involvement of the renin-angiotensin system (RAS) in CsA toxicity, but the issue is still controversial in more ways than one....

  • Comprehensive Diabetes Care: The Whole Enchilada. Kuritzky, Louis // Internal Medicine Alert;3/29/2008, Vol. 30 Issue 6, p48 

    The article focuses on a study on diabetics which demonstrated that although glucocentric focus in diabetes produces microvascular benefits, dealing with the factors like blood pressure (BP), lipids, the renin-angiotensin system, and platelets benefits the patient.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics